Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Nerispirdine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.65 |
| ▸ | BCHE | P06276 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nerispirdine SCHEMBL3842518 | 0.99 | SLC6A2 (0.67) | SLC6A2BCHECYP2D6 | |
| Nerispirdine SCHEMBL29379158 | 0.99 | SLC6A2 (0.67) | SLC6A2BCHECYP2D6 | |
| SCHEMBL8946036 | 0.89 | BCHE (0.54) | SLC6A2BCHECYP2D6 | |
| SCHEMBL8442522 | 0.88 | SLC6A2 (0.71) | SLC6A2BCHECYP2D6 | |
| Hydrochloric Acid SCHEMBL7609627 | 0.85 | SLC6A2 (0.49) | SLC6A2BCHECYP2D6 | |
| SCHEMBL7613191 | 0.85 | SLC6A2 (0.67) | SLC6A2BCHECYP2D6 | |
| SCHEMBL13570044 | 0.85 | SLC6A2 (0.67) | SLC6A2BCHECYP2D6 | |
| SCHEMBL9671889 | 0.84 | BCHE (0.58) | SLC6A2BCHE | |
| Hydrochloric Acid SCHEMBL7613979 | 0.84 | SLC6A2 (0.48) | SLC6A2BCHECYP2D6 | |
| SCHEMBL7614150 | 0.84 | SLC6A2 (0.50) | SLC6A2BCHECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420593-B1 | Compositions and methods for regulating membrane potential | MILLER LANDON C G (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2138176-A1 | Method of treating cognitive impairment | Aventis Pharmaceuticals Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090281147-A1 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-12 | — | — | US | disclosed |
| EP-1734959-B1 | COMPOUNDS FOR TREATING SCHIZOPHRENIA AND/OR GLUCOREGULATORY ABNORMALITIES | AVENTIS PHARMA INC (US) | 2009-10-28 | — | — | EP | disclosed |
| US-7534803-B2 | Method of treating demyelinating diseases or conditions | AVENTIS PHARMACEUTICALS INC. (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1678135-B1 | PROCESS FOR THE PREPARATION OF N-AMINO SUBSTITUTED HETEROCYCLIC COMPOUNDS | AVENTIS PHARMA INC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-7230015-B2 | Method of treating of demyelinating diseases or conditions | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070129403-A1 | METHOD OF TREATING SCHIZOPHRENIA AND/OR GLUCOREGULATORY ABNORMALITIES | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179821-B2 | Method of treating of demyelinating diseases or conditions | AVENTIS PHARMACEUTICALS INC. (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1734959-A2 | METHOD OF TREATING SCHIZOPHRENIA AND/OR GLUCOREGULATORY ABNORMALITIES | Aventis Pharmaceuticals, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-5776955-A | Use of unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents | HOECHST MARION ROUSSEL, INC. | 1998-07-07 | — | — | US | disclosed |
| EP-0840609-A1 | USE OF UNSUBSTITUTED AND SUBSTITUTED N-(PYRROL-1-YL)PYRIDINAMINES AS ANTICONVULSANT AGENTS | HOECHST MARION ROUSSEL, INC. (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997004777-A1 | USE OFF UNSUBSTITUTED AND SUBSTITUTED N-(PYRROL-1-YL)PYRIDINAMINES AS ANTICONVULSANT AGENTS | HOECHST MARION ROUSSEL, INC. (US) | 1997-02-13 | — | — | WO | disclosed |
| EP-0635269-A1 | Use of N-(Pyridinyl)-1H-Indol-1-Amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-01-25 | — | — | EP | disclosed |
| EP-0287982-B1 | N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5356910-A | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-10-18 | — | — | US | disclosed |
| US-5039811-A | Analgesics, antidepressants, memory activators; condensation, reduction | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-08-13 | — | — | US | disclosed |
| US-4970218-A | ANALGESIC, ANTIDEPRESSANT, MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-11-13 | — | — | US | disclosed |
| US-4880822-A | COGNITION ACTIVATORS, ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0287982-A2 | N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129403-A1 | METHOD OF TREATING SCHIZOPHRENIA AND/OR GLUCOREGULATORY ABNORMALITIES | HCRTR1, CBR1, SLC5A1 | SLC6A2 64/4885BCHE 463/4885CYP2D6 1146/4885 |
| US-20090281147-A1 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS | PMP22, BDKRB1, BDKRB2 | SLC6A2 1049/4885BCHE 977/4885CYP2D6 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.